Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
All India, South India, Central India, North India, East India, West India, Andaman and Nicobar Islands, Andhra Pradesh, Assam, Arunachal Pradesh, Bihar, Chhattisgarh, Chandigarh, Delhi, Dadra and Nagar Haveli, Daman and Diu, Gujarat, Goa, Haryana, Himachal Pradesh, Jammu and Kashmir, Jharkhand, Karnataka, Kerala, Lakshadweep, Madhya Pradesh, Maharashtra, Mizoram, Meghalaya, Manipur, Nagaland, Odisha, Punjab, Pondicherry, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Uttar Pradesh, Uttarakhand, West Bengal
GMP/WHOGMP/NAFDAC/COA/COPP/Manufacturing License/Free sale certificate/Dossier.
The combination of nirmatrelvir tablets and ritonavir tablets is a product that the FDA is allowing to be given for emergency use to treat COVID-19. It is used by people 12 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 5 days and are not hospitalized.